From March 8 to 13, 2026, the International Forum on Quality and Safety in Healthcare was held in Oslo, Norway. Marking its 30th anniversary, the event was co-hosted by BMJ Group (BMJ) and the Institute for Healthcare Improvement (IHI), with support from the Norwegian Directorate of Health and other authorities, standing as a globally influential conference in healthcare quality and safety. At the invitation of BMJ, Gu Chengming, Marketing Director of Yangtze River Pharmaceutical Group (“YRPG” or “the Group”), led a high-level Chinese delegation consisting of officials from the Chinese Hospital Association (CHA) and senior hospital leaders across China to attend the forum.
This event marks a key milestone in the Group’s global development strategy. Leveraging BMJ’s worldwide medical and academic resources, the Group aims to broaden its global vision, explore innovative hospital-enterprise cooperation models, build an international platform for healthcare knowledge sharing, strengthen global academic influence, and help share China’s healthcare expertise with the world.
The delegation fully participated in core sessions including the high-level leadership summit, keynote speeches, parallel forums, and the BMJ Editors’ Meeting. At the leadership summit, Chinese representatives engaged in in-depth exchanges with international experts such as Sylvia Trent-Adams, Chief Executive Officer of IHI, and officials from the Norwegian Directorate of Health, focusing on addressing healthcare trust crises and strengthening systemic resilience. Formally introduced during the conference, the delegation demonstrated the professionalism and collaborative commitment of China’s healthcare community. Throughout the forum, the delegation actively shared China’s practical achievements in healthcare quality improvement, patient safety and digital health, drawing extensive attention from global peers.
The Chinese delegation also conducted on-site visits to top-tier Norwegian medical institutions including Diakonhjemmet Hospital, gaining insights into their patient-centered service models, digital management systems and specialized discipline development practices. During exchanges with the editorial team of the BMJ, both sides discussed academic publication, research topic selection and international collaboration. Chinese experts presented relevant research outcomes, receiving positive feedback and professional guidance from the BMJ team.
This trip to Norway has built an effective bridge for China’s healthcare sector to conduct international exchanges and participate in global health governance. It has also accumulated international experience and expanded cooperation channels to advance the development of healthcare quality and safety in China.
Moving forward, the Group will continue to collaborate with international partners including the BMJ to launch more high-level exchange platforms, accelerate its international development, and help bring China’s healthcare expertise to the global stage.